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RESEARCH ARTICLE
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Two previous studies concluded that proenkephalin A (PENK-A) had predictive capabilities
for stroke severity, recurrent myocardial infarction, heart failure and mortality in patients with
stroke and myocardial infarction.
Objectives
This study aimed to investigate the value of PENK-A as a biomarker for predicting mortality
in patients with type 2 diabetes mellitus.
Methods
Patients with type 2 diabetes mellitus were included from the prospective observational
ZODIAC (Zwolle Outpatient Diabetes project Integrating Available Care) study. The present
analysis incorporated two ZODIAC cohorts (1998 and 2001). Since blood was drawn for
1204 out of 1688 patients (71%), and information on relevant confounders was missing in
47 patients, the final sample comprised 1157 patients. Cox proportional hazard models
were used for evaluating the relationship between PENK-A and (cardiovascular) mortality.
Risk prediction capabilities were assessed with Harrell’s C statistics and the integrated dis-
crimination improvement (IDI).
Results
After a follow-up period of 14 years, 525 (45%) out of 1157 patients had died, of which 224
(43%) were attributable to cardiovascular factors. Higher Log PENK-A levels were not inde-
pendently associated with increased (cardiovascular) mortality. Patients with PENK-A
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values in the highest tertile had a 49% (95%CI 1%-121%) higher risk of cardiovascular
mortality compared to patients in the reference category (lowest tertile). C-values were not
different after removing PENK-A from the Cox models and there were no significant differ-
ences in IDI values.
Conclusions
The associations between PENK-A and mortality were strongly attenuated after accounting
for all traditional risk factors. Furthermore, PENK-A did not seem to have additional value
beyond conventional risk factors when predicting all-cause and cardiovascular mortality.
Introduction
The opioid peptide enkephalin is found in brain and endocrine tissues and has effects on neu-
roendocrine and nociceptive responses [1][2]. Enkephalin expression in the hypothalamus is
stimulated in response to fat consumption and is thought to inhibit nociceptive responses in
the spinal cord [3][4]. Enkephalins are also expressed by pancreatic islets cells [5], and have an
inhibitory effect on the insulin response through inhibiting glucose absorption [6]. Further-
more, a variety of other physiological effects have been described, for example its influence on
heart rate and blood pressure [7].
As enkephalins have a very short half-life, a stable precursor fragment of enkephalin (proen-
kephalin A (PENK-A)) has been developed and investigated in clinical studies [8]. Given the
physiological effects, enkephalins have the potential to function as biomarkers for disease pre-
diction. Two previous studies indeed showed that PENK-A levels had prognostic capabilities in
patients with stroke and myocardial infarction [9][10]. Serum levels of PENK-A were related
to stroke severity, recurrent myocardial infarction, heart failure and mortality [9][10].
No previous studies with either long-term follow-up, nor studies specifically in patients
with type 2 diabetes mellitus (T2DM) have been performed. We hypothesized that increased




This prospective observational study of primary care treated patients is part of the ZODIAC
(Zwolle Outpatient Diabetes project Integrating Available Care) study; the design and details
of which have been presented elsewhere [11]. This project started in 1998 in Zwolle, The Neth-
erlands, and is still ongoing. Briefly, the aim of the parent study was to study the effects of two
different shared care interventions in patients with T2DM. The main findings were that struc-
tured shared care with task delegation to nurses appeared feasible and could positively affect
quality of care for patients with T2DM [11]. The present study is a secondary analysis of the
ZODIAC study to assess the predictive capability of PENK-A, and comprises two cohorts of
the ZODIAC study: one cohort started at the beginning in 1998 and the other in 2001 [12].
The first cohort contained 1143 patients and the second cohort included 973 patients, of which
427 patients were already participating in the ZODIAC study since 1998. Therefore, the com-
bined cohort consisted of 1688 patients.
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Data collection
Baseline data consisting of a full medical history were collected in 1998 and 2001. Patients were
considered to have macrovascular complications when they had a previous history of angina
pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty, coronary
artery bypass grafting, stroke, or transient ischaemic attack. Physical and laboratory assessment
data, such as blood pressure, body mass index, lipid profile, creatinine levels, HbA1c and uri-
nary albumin-creatinine ratio, were collected annually. Blood pressure was measured twice
with a Welch Allyn Sphygmomanometer in supine position after at least five minutes of rest.
The mean blood pressure of two recordings was calculated for each visit.
Measurement of proenkephalin A
Since mature enkephalins that derive from the PENK-A precursor peptide, are unstable bioac-
tive peptides, an immunoassay has been developed that measures a stable precursor fragment
of PENK-A, termed PENK-A 119–159 [8]. The abbreviation PENK-A used in this manuscript
refers to this precursor fragment. PENK-A was measured using a sandwich immunoassay, in
1204 out of the 1688 (71.3%) patients using serum collected at baseline and kept frozen at -80
degrees Celsius until analysis according to the instructions of the manufacturer (B.R.A.H.M.S.
GmbH, Hennigsdorf/Berlin, Germany). The functional assay sensitivity of this assay is 18.5
pmol/L (20% CV) (unpublished data).
Clinical endpoints
There were two clinical endpoints: all-cause and cardiovascular mortality. The vital status and
cause of death were retrieved from records maintained by the hospital and the general practi-
tioners up to the end of 2012. Causes of death were coded according to The International Clas-
sification of Diseases, 9th revision (ICD-9). Cardiovascular mortality was defined as any death
in which the principal cause of death was cardiovascular in nature (ICD-9 codes 390–459).
Statistical analyses
Analyses were performed with SPSS version 18.0 (SAS Institute, Cary, NC, USA) and STATA
version 12 (StataCorp, College Station, Texas USA). Continuous variables are represented as
mean (± standard deviation) for normally distributed values and as median [interquartile
range] for the non-normally distributed variables. Normality of the variables was examined by
inspecting Q-Q plots. Univariate linear regression analyses were used to investigate whether
PENK-A concentrations were associated with several clinical parameters. Due to a skewed dis-
tribution, PENK-A and serum creatinine were logarithmically transformed.
Multivariate linear regression models were used to assess the association between PENK-A
and baseline characteristics. Cox proportional hazards models were used to investigate the
relationship between the serum concentration PENK-A, as a continuous and a categorical
(PENK-A divided into tertiles) variable, and all-cause and cardiovascular mortality with and
without adjustment for selected confounders. We used 1. an unadjusted model, 2. an age- and
gender-adjusted model, and 3. a model in which we additionally adjusted for the following var-
iables: duration of diabetes, smoking (dichotomous), macrovascular complications (dichoto-
mous), body mass index (BMI), systolic blood pressure, HbA1c, serum creatinine, cholesterol-
HDL ratio and albuminuria (dichotomous). Because of missing information regarding albu-
minuria, BMI, smoking and duration of diabetes in 33, 2, 6 and 6 patients respectively, all
analyses were performed in 1157 out of 1204 patients (96%) whose PENK-A values were deter-
mined. STATA’s ph-tests were used to test the assumption of proportional hazards for baseline
PENK-A and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0133065 July 28, 2015 3 / 10
predictors. Survival curves were used to illustrate the relationship between PENK-A and
mortality.
For assessing the prognostic capabilities of PENK-A, we performed the following analyses
stepwise. First, calibration was investigated using the Grønnesby and Borgan test assessing the
goodness of fit; a nonsignificant result means an acceptable calibration [13]. Calibration is a
measure of how well predicted probabilities agree with actual observed risk. Second, the Har-
rell’s C statistic was used to investigate the capability of each model to predict mortality and to
compare how well the presence of PENK-A, in the different models used, predicted mortality
[14]. The Harrell’s C value is a rank-based measure (more or less comparable with the area
under the receiver operating characteristic curve). The higher the value, the better the model
predicts mortality. Third, the integrated discrimination improvement (IDI) was calculated
[15]. The IDI can be interpreted as the difference between model-based probabilities for events
and non-events for the models with and without PENK-A. Finally, the proportion of variation
explained by the survival model was estimated using R2 (D-method) [16].
In addition to investigate whether the relationship between PENK-A and mortality was
affected by other clinical variables, interaction terms were added to model 3. Interaction was
tested when variables were associated with PENK-A in the multivariate linear regression analy-
ses. Interaction was evaluated as significant at a p-value of 0.10 [17].
Ethics statement
Both cohorts of the ZODIAC study (1998 and 2001) and the informed consent procedure were
approved by the local medical ethics committee of the Isala hospital, Zwolle, The Netherlands.
Verbal informed consent was obtained for all patients by the participating diabetes specialist
nurses and the consent was documented in the patients records. According to Dutch law, writ-
ten informed consent was not necessary for this type of study in 1998 and 2001. All data were
analysed anonymously.
Results
The baseline characteristics are presented in Table 1. The median [interquartile range]
PENK-A concentration was 112 [91–143] pmol/L. There were no relevant or significant differ-
ences between the final study group and those subjects without PENK-A measurements
(n = 285). In the multivariate regression analyses, higher age, female gender and higher serum
creatinine levels were associated with higher PENK-A levels (Table 1). Furthermore, higher
HbA1c levels and BMI were related to lower PENK-A levels.
After a follow-up period of 14 years, 525 (45%) patients had died of which 224 (43%) were
attributed to cardiovascular causes. A total of 13 patients were lost to follow-up (1%) and cause
of death was unknown for 25 patients (5%). The median serum concentration PENK-A in the
survivors was 103 [84–132] pmol/L, compared with 126 [97–159] pmol/L in the deceased
patients. Results of the Cox regression analyses are presented in Table 2. Higher levels of log
PENK-A were related to increased all-cause and cardiovascular mortality in the unadjusted
and in the age- and gender adjusted analyses (models 1 and 2). After adjustment for all selected
confounders (model 3), the relationships were not significant. Figs 1 and 2 show the survival
curves of the fully adjusted models, in which PENK-A was divided into tertiles. Patients with
PENK-A concentrations in the highest tertile had an increased risk of cardiovascular mortality
compared to the reference category, even after adjustment for all selected confounders (Table 2
and S1 Statistical Analyses). All p-values for the ph-test were non-significant, meaning that no
substantial deviations were observed.
PENK-A and Mortality
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Table 1. Baseline characteristics and results of the multivariate linear regression models.
Total Tertile 1 Tertile 2 Tertile 3 Beta coefﬁcient
Characteristic n = 1157 n = 385 n = 389 n = 383 (95% CI)
Proenkephalin A (pmol/L) 112 [91–143] 81 [69–79] 112 [104–123] 158 [144–185] NA
Age (years) 66.6 (± 11.6) 61.7 (± 11.4) 66.0 (± 10.5) 72.2 (± 10.4) 0.007 (0.005; 0.009)
Female sex 637 (55.1%) 189 (49.1%) 198 (50.9%) 250 (65.3%) 0.175 (0.135; 0.216)
Diabetes duration (years) 4 [2–9] 4 [2–8] 4 [2–9] 4 [2–10] 0.002 (-0.001; 0.005)
Smokers 217 (18.8%) 98 (25.5%) 63 (16.2%) 56 (14.6%) 0.000 (-0.049; 0.049)
Macrovascular complications 412 (35.6%) 119 (30.9%) 128 (32.9%) 165 (43.1%) 0.018 (-0.021; 0.058)
Body mass index (kg/m2) 29.2 (± 4.8) 30.6 (± 5.1) 29.2 (± 4.4) 27.8 (± 4.5) -0.013 (-0.017; -0.009)
Systolic blood pressure (mmHg) 152.0 (± 23.8) 148.8 (± 24.1) 152.9 (± 23.1) 154.3 (± 23.9) 0.000 (-0.001; 0.001)
HbA1c (%) [mmol/mol] 7.2 (± 1.3) [55] 7.5 (± 1.4) [58] 7.2 (± 1.3) [55] 7.0 (± 1.3) [53] -0.033 (-0.048; -0.018)
Serum creatinine (umol/L) 92 [82–103] 88 [79–98] 92 [83–102] 96 [86–112] 0.007 (0.006; 0.008)
Cholesterol-HDL ratio (mmol/L) 4.9 (± 1.5) 5.0 (± 1.4) 4.9 (± 1.6) 4.8 (± 1.5) -0.002 (-0.015; 0.011)
Albuminuria present 453 (39.2%) 146 (37.9%) 156 (40.1%) 151 (39.4%) -0.020 (-0.059; 0.019)
Data are means (± SD), medians [interquartile range] or n (%). One-way ANOVA, Chi square, or Kruskal-Wallis test was used where appropriate to test
for differences between groups.
doi:10.1371/journal.pone.0133065.t001
Table 2. Results of the Cox regression analyses, the comparison of predictive capability for mortality as determined by the Harrell’s C statistic,
and the IDI for adding the peptide to models 2 and 3, respectively.
n Model 1 Model 2 Model 3HR (95%CI)
HR (95%CI) HR (95%CI) HR (95%CI)
All-cause mortality
Tertile 1 385 1 (reference) 1 (reference) 1 (reference)
Tertile 2 389 1.33 (1.06–1.67) 0.98 (0.78–1.23) 1.05 (0.83–1.33)
Tertile 3 383 2.33 (1.88–2.89) 1.12 (0.90–1.41) 1.06 (0.83–1.35)
Log PENK-A 1157 3.27 (2.56–4.18) 1.33 (1.02–1.73) 1.09 (0.81–1.46)
Harrell’s C 0.62 (0.59–0.64) 0.77 (0.75–0.79) 0.80 (0.78–0.82)
Harrell’s C* NA 0.77 (0.75–0.79) 0.80 (0.78–0.82)
R2 (95%CI) 0.10 (0.06–0.15) 0.49 (0.42–0.55) 0.58 (0.53–0.65)
IDI % (95%CI) NA 0.1 (-0.1–0.3) 0.0 (-0.1–0.1)
Cardiovascular mortality
Tertile 1 385 1 (reference) 1 (reference) 1 (reference)
Tertile 2 389 1.50 (1.03–2.21) 1.14 (0.77–1.67) 1.24 (0.84–1.82)
Tertile 3 383 3.37 (2.38–4.75) 1.77 (1.23–2.54) 1.49 (1.01–2.21)
Log PENK-A 1157 4.99 (3.44–7.24) 2.31 (1.52–3.50) 1.45 (0.91–2.30)
Harrell’s C 0.65 (0.62–0.69) 0.76 (0.73–0.79) 0.82 (0.79–0.84)
Harrell’s C* NA 0.76 (0.73–0.79) 0.82 (0.79–0.84)
R2 (95%CI) 0.18 (0.10–0.28) 0.49 (0.40–0.59) 0.67 (0.60–0.76)
IDI % (95%CI) NA 1.3 (0.6–2.0) 0.2 (-0.1–0.6)
Abbreviations: IDI, integrated discrimination improvement HR, hazard ratio; CI, conﬁdence interval; NA, not applicable.
* Harrell’s C values for the models without PENK-A. Model 1: crude model. Model 2: adjusted for age and gender. Model 3: adjusted for age, gender,
duration of diabetes, smoking (dichotomous), macrovascular complications (dichotomous), body mass index, systolic blood pressure, HbA1c, serum
creatinine, cholesterol-HDL ratio and albuminuria (dichotomous).
doi:10.1371/journal.pone.0133065.t002
PENK-A and Mortality
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After adding an interaction between serum creatinine and PENK-A to model 3, this interac-
tion was only significant in the model with all-cause mortality (p = 0.019) (S2 and S3 Statistical
analyses). For each quartile of serum creatinine survival plots were created illustrating the rela-
tionship between PENK-A (in quartiles) and mortality. The same plots were created for each
quartile of PENK-A, in which the relationship between serum creatinine and mortality was
illustrated. These plots showed that the mortality rates in patients with the highest PENK-A
levels increased with higher serum creatinine values (S4 Statistical analyses). Also, the mortality
rate in patients wither higher serum creatinine levels increased with higher PENK-A values. In
a post-hoc explanatory analysis without serum creatinine, PENK-A was significantly and
independently associated with all-cause and cardiovascular mortality (S2 and S3 Statistical
analyses).
The Grønessby and Borgan test indicated that predicted probabilities corresponded well
with observed risks and all models were well calibrated (data not shown). So, the number of
deceased patients as estimated by the model is in line with the number of patients that actually
died. According to the Harrell C statistic (Table 2), model 3 is the most capable for predicting
mortality. C-values were not different after removing PENK-A from models 2 and 3. R^2
increased with adding more variables to the model. A significant IDI was only found in model
2 for cardiovascular mortality.
Discussion
After adjustment for all traditional cardiovascular risk factors, we observed no independent
association between PENK-A, as a continuous variable, and mortality. Although patients with
Fig 1. Survival curve all-causemortality. Relationship of PENK-A, divided into tertiles, and all-cause.
Tertile 1: blue line, tertile 2: green line, tertile 3: grey line.
doi:10.1371/journal.pone.0133065.g001
PENK-A and Mortality
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the highest PENK-A concentrations had a 49% higher risk of cardiovascular mortality com-
pared to patients with the lowest concentrations, the association was strongly attenuated after
adjusting for all traditional risk factors. These results put conclusions from previous studies in
a different perspective [9][10].
Previous studies
Notably, the 2 previous studies that both claimed that PENK-A was promising as a biomarker,
did not systematically adjust for the same important risk factors as we did in our study [9][10].
Although a relevant association between PENK-A as a continuous variable and mortality
(given the width of the 95% CI, model 3) could not be excluded in this study, the associations
were attenuated after adding other confounders. In our post-hoc analyses without serum creat-
inine, PENK-A was significantly and independently associated with all-cause and cardiovascu-
lar mortality. These results could suggest that PENK-A is a biomarker for renal function.
However, Ng et al. adjusted for the estimated glomerular filtration rate (eGFR), and therefore it
seems unlikely that serum creatinine is the only missing confounder. Doehner et al. only
adjusted for age, stroke severity and brain lesion size, and Ng et al., although correcting for
eGFR, did not include smoking, BMI, albuminuria and cholesterol in the multivariate analyses
[9]. Therefore, the results of both previous could have been influenced by unmeasured con-
founders for which we were able to adjust for.
Fig 2. Survival curve cardiovascular mortality.Relationship of PENK-A, divided into tertiles, and
cardiovascular mortality. Tertile 1: blue line, tertile 2: green line, tertile 3: grey line.
doi:10.1371/journal.pone.0133065.g002
PENK-A and Mortality
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Risk prediction
Although the IDI showed a significant improvement in discrimination for cardiovascular mor-
tality prediction for the age- and gender-adjusted PENK-A levels, care must be taken to rely on
these results because measures like IDI are not developed in the context of censored data. In
addition, serious criticism has been published against the use of IDI and NRI indices [18][19].
Simulation results show that these measures can show predictive improvement even when
non-informative predictors are added to a prediction model [20]. The addition of PENK-A to
the age- and gender-adjusted models did not increase the C values. Although we cannot
exclude that PENK-A has a role in risk prediction when PENK-A is studied as a single marker,
there was no additional value when all traditional cardiovascular risk factors were available, at
least not for mortality prediction in patients with T2DM. This study confirmed previous stud-
ies that it is difficult to achieve improvements in risk prediction by adding a biomarker to mod-
els with all conventional risk factors [21].
Strengths and limitations
Strengths of this study were the prospective design, the high event rate (cause of death was
available for 501 patients out of 525 deceased patients) and the long follow-up period. This
study also had several important limitations. Firstly, the observational design prevented us
from drawing conclusions on causality. Secondly, the serum concentration of PENK-A was
assessed in 71% of the total study population, which could have led to selection bias. However,
no relevant differences were observed in baseline variables between the final study group and
those subjects without PENK-A measurements (n = 285). Furthermore, missing of PENK-A
data was related to mortality and this could have led to an underestimation of the effects of
PENK-A on mortality (HR all-cause mortality 1.20 (95% confidence interval 1.00–1.44)). Fur-
thermore, PENK-A was measured only once, therefore potential daily variability in concentra-
tion or measurement errors could not be accounted for.
Conclusions
Serum PENK-A levels were not independently associated with all-cause mortality in patients
with type 2 diabetes mellitus, and its association with cardiovascular mortality was strongly
attenuated after accounting for all traditional risk factors. Furthermore, PENK-A did not seem
to have additional value beyond conventional risk factors when predicting all-cause and car-
diovascular mortality. The results of this study show that is plausible that the results from two
previous studies could have been influenced by residual confounding. Future studies assessing
the prognostic capabilities of PENK-A should systematically account for all important cardio-
vascular risk factors.
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